Kenai Therapeutics
Kenai Therapeutics is a biotechnology company developing allogeneic neuron replacement cell therapies for neurological disorders using induced pluripotent stem cell (iPSC) technology. Their lead candidate, RNDP-001, targets Parkinson's disease and has shown promising results in preclinical models. The company aims to provide curative treatments for patients with limited treatment options.
Funding Round: Series A
Funding Amount: $82M
Date: 29-Feb-2024
Investors: Alaska Permanent Fund Corporation, Cure Ventures, The Column Group, Euclidean Capital, Saisei Ventures
Markets: Biotechnology, Cell Therapy, Neurology, Drug Discovery
HQ: San Diego, California, United States
Founded: 2022
Website: https://www.kenaitx.com
LinkedIn: https://www.linkedin.com/company/kenaitx
Leave a Comment
Comments
No comments yet.